Expression and clinical significance of interleukin-10, transforming growth factor-β1, and CD4+CD25 cytokines in paediatric allergic rhinitis with allergic asthma

• Published in: Postȩpy dermatologii i alergologii Vol. 41; no. 3; pp. 276 - 283
• Main Authors: Chen, Jing, Wang, Shuyu, Cheng, Yan, Wang, Fukun, Liu, Xuechao
• Format: Journal Article
• Language: English
• Published: Poland Termedia Publishing House 01.06.2024
• Subjects: Original Paper; CD4+CD25; allergic asthma; interleukin-10; transforming growth factor β1; paediatric allergic rhinitis
• ISSN: 1642-395X; 2299-0046
• DOI: 10.5114/ada.2024.140522

It was intended to research the level changes and clinical significance of interleukin (IL)-10, transforming growth factor β1 (TGF-β1), and CD4+CD25 cytokines in paediatric allergic rhinitis (AR) accompanied with allergic asthma (AA). Eighty children of AA with AR receiving immunotherapy indications were included as the experimental group (EG), while another 40 healthy children in the same period were selected as the control group (CG). IL-10, TGF-β1, and CD4+CD25 levels in cells of the two groups before and after treatment were compared and analysed. The serum TGF-β1 level was determined as 1,045.7 ±44.7 pg/ml in the EG at admission, remarkably higher than that in the CG ( < 0.05). The IL-10 level was 21.4 ±2.8 pg/ml; CD4+CD25 cells accounted for 9.2 ±2.4%, CD4+CD25 cells accounted for 0.6 ±0.3%. These were all greatly lower than those in the CG ( < 0.05). At discharge, the serum TGF-β1 level in the EG was 903.7 ±29.4 pg/ml, which was still memorably higher than that in the CG ( < 0.05). The IL-10 level changed to 32.8 ±3.7 pg/ml; the percentage of CD4+CD25 was 11.3 ±1.8, respectively, among CD4+T cells. These were also notably lower than those in the CG at discharge ( < 0.05). IL-10, TGF-β1, and CD4+CD25 level changes in cells might be of reference value as therapeutic indicators for clinical treatment or evaluation of paediatric AR with AA.